Propanc Biopharma Faces Nov. 2 Nasdaq Delisting Without Appeal by Oct. 30
Propanc Biopharma (PPCB) received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price requirement. The company must appeal by October 30, 2026, to avoid delisting on November 2, 2026. Propanc claims it has cured the deficiency and will request an appeal, which would stay the delisting until a panel decision. Delisting could negatively impact liquidity, market price, and access to capital markets.
How this was made
The 30-second read
Why it matters
The delisting risk creates immediate downside pressure; the appeal outcome will drive short‑term price movement.
Market read
The notice introduces significant risk for PPCB shareholders and may affect sentiment toward other low‑priced biotech stocks on Nasdaq.
What to watch
Possibility of a reverse split or migration to an alternative exchange to restore compliance.
Background
Propanc Biopharma received a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement and will be delisted on Nov 2 unless it appeals by Oct 30. The company plans to request an appeal, believing it has cured the deficiency.
Ticker impact
Nasdaq delisting notice for Propanc Biopharma due to failure to meet the $1.00 minimum bid price, with an appeal deadline of Oct 30, 2026.
likely pressure as the market prices in potential delisting risk
The notice is a primary disclosure of a material corporate action with a tight deadline, prompting traders to consider exiting or short positions.
Market effects
May increase scrutiny on other low‑priced Nasdaq biotech and small‑cap stocks.
Potential modest dip in Nasdaq small‑cap index as investors reassess similar listings.
Limited to US biotech and small‑cap markets.
Counterpoint
If the appeal succeeds, the stock could rally on relief and renewed confidence.
Key entities
- companyPropanc Biopharma
Biopharma company listed on Nasdaq (ticker PPCB) facing delisting notice.
- exchangeNasdaq
US stock exchange issuing the delisting notice.
